about
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingSKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.Identification of a Novel Family of BRAF V600E InhibitorsFunctional profiling of live melanoma samples using a novel automated platformEnhancing the evaluation of PI3K inhibitors through 3D melanoma models.The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation.Organometallic Pyridylnaphthalimide Complexes as Protein Kinase Inhibitors.A stress-induced early innate response causes multidrug tolerance in melanoma.Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimizationRhenium complexes with visible-light-induced anticancer activity.Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.Beyond structure, to survival: activation of Stat3 by cadherin engagement.Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.PIM kinases as therapeutic targets against advanced melanoma.Targeting BRAF in advanced melanoma: a first step toward manageable disease.In situ electroporation of large numbers of cells using minimal volumes of material.The role of Orai-STIM calcium channels in melanocytes and melanoma.The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.Differential effects of c-Ras upon transformation, adipocytic differentiation, and apoptosis mediated by the simian virus 40 large tumor antigen.Stat3 is required for full neoplastic transformation by the Simian Virus 40 large tumor antigen.Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells.Growth and isotopic labelling of adherent cells in small volumes of medium.Examination of gap junctional, intercellular communication by in situ electroporation on two co-planar indium-tin oxide electrodesTargeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma.Differential effects of Stat3 inhibition in sparse vs confluent normal and breast cancer cells.Electroporation of adherent cells in situ for the study of signal transduction and gap junctional communication.Cadherin-cadherin engagement promotes cell survival via Rac1/Cdc42 and signal transducer and activator of transcription-3.Gap junctional intercellular communication in cells isolated from urethane-induced tumors in A/J mice.In situ electroporation of radioactive compounds into adherent cells.Stat3 activity is required for gap junctional permeability in normal rat liver epithelial cells.Meeting report from the 10th International Congress of the Society for Melanoma Research, Philadelphia, PA, November 2013.A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma.The promise of 3D skin and melanoma cell bioprinting.BRAF inhibitor unveils its potential against advanced melanoma.
P50
Q21133611-D7E553FE-C9AA-49D7-87C2-B4DE491CB02DQ24656966-397336A3-9773-4F77-98BD-741E63E68CADQ27678754-EAD12A6D-ABAE-4DBB-882F-C5A9C8ECC11CQ28484649-D402226E-C6E3-45B3-8AA8-45DF89651C96Q30746265-73754BEA-43FC-4AAE-B1F9-C32511E92AFAQ34105950-48241A81-9B6F-4293-B93A-B1179996BF74Q35207714-A09B94F5-8707-446F-90DF-11B3125B7AEAQ35639898-80DD76CD-566D-4158-A584-44AFA961D5FAQ36189476-B92916DA-7C19-4A55-92BE-A0B7E6B2409BQ36881314-2B2EF3DE-6103-41D6-95F1-8FC3DF71ACB9Q37401245-7F5625C4-913A-4A76-A859-0565C31D3594Q37570262-21C9B6A6-CA09-4A98-B62C-E844634E5912Q37638228-13478997-E25A-4A97-9EE2-6083D6215C70Q37641646-56467C16-78B1-4794-B854-D127249BCE95Q37688157-B9CDCF93-AB05-41BE-BE2B-7AC0AB1007DDQ37859164-E26A6AE3-0EAE-450B-B306-CB0CA015C424Q38355005-F6A3DC2A-9000-4149-9D4A-F93D2F7B2254Q38728876-F1660191-B2F0-4C87-B348-B58FC758590BQ39195579-7CED866C-8A4F-4545-A9DF-2E20DED428E6Q39703155-1B3CD89F-CA3E-4363-8DCF-89284C581A89Q40140319-E3636981-7C97-4D4D-A0C0-35436DB04476Q40417149-BCC98D57-7AA7-4385-AAB4-6BF35C515794Q40580990-DC4739AE-8B91-43E8-B923-A30FA9BD88C9Q40750493-D49DF1D4-41E6-4A16-88C3-4C6A5B8EC1B7Q41252071-FCD7C25C-6F3B-458D-986E-A1EE5738F066Q42317543-FB6BC5AE-56C7-404B-B542-310FFA0CD22DQ42806654-EC5A0A89-8891-45B2-9050-80DD568E1D92Q42815188-BCDD8765-4BBA-4FF2-93D9-4DBB7C9F5CC2Q43293853-671745B8-DDE9-4BF1-8783-1C5F4EB1AC1CQ44318620-F7C93EF8-35B8-497C-9942-455A9789F4AEQ44563508-76A5D256-236E-4E5B-9FAA-2CA447FD8FEFQ45233512-BBE8E98E-7141-40C1-8A43-65553AAD4432Q47099137-01EE24C3-904D-4E3F-AC3D-0F1F9BA614C0Q47123308-F1D89BF6-A7DA-4FF6-9B33-014D145FC6ACQ47577367-9A8A784D-3CE7-4644-AD8C-C71D5789DEF5Q49450264-61906F78-2FE9-4B0C-B82A-D64DB061411CQ51483444-ACAA481D-DCAC-450E-97C9-DBCF67B9D033Q54642349-7854242E-FD22-47A2-A886-666A587A572A
P50
description
researcher ORCID ID = 0000-0003-0068-9496
@en
wetenschapper
@nl
name
Adina Vultur
@ast
Adina Vultur
@en
Adina Vultur
@es
Adina Vultur
@nl
type
label
Adina Vultur
@ast
Adina Vultur
@en
Adina Vultur
@es
Adina Vultur
@nl
prefLabel
Adina Vultur
@ast
Adina Vultur
@en
Adina Vultur
@es
Adina Vultur
@nl
P108
P31
P496
0000-0003-0068-9496